High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer
Variants of survivin with differing subcellular localizations might mediate the different functions of survivin, i.e. cell-cycle regulation and apoptosis inhibition. Highly proliferative tumors are more sensitive to chemotherapy, whereas apoptosis resistant cells would be refractory to endocrine the...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2006-07, Vol.98 (2), p.223-230 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 230 |
|---|---|
| container_issue | 2 |
| container_start_page | 223 |
| container_title | Breast cancer research and treatment |
| container_volume | 98 |
| creator | SPAN, Paul N TJAN-HEIJNEN, Vivianne C. G MANDERS, Peggy VAN TIENOVEN, Doorlene LEHR, Jeffrey SWEEP, Fred C. G. J |
| description | Variants of survivin with differing subcellular localizations might mediate the different functions of survivin, i.e. cell-cycle regulation and apoptosis inhibition. Highly proliferative tumors are more sensitive to chemotherapy, whereas apoptosis resistant cells would be refractory to endocrine therapy. Possibly, this explains incongruent data on the association of survivin with prognosis in breast cancer. Survivin levels were measured using ELISA in 800 x g pellets and 100,000 x g supernatants of breast cancer tissues from patients that were treated with either chemotherapy or endocrine therapy for advanced disease. These fractions might be enriched with nuclear or cytoplasmatic located survivin variants. Survivin levels were associated with tumors with poor prognostic clinical characteristics. For the patients treated with endocrine therapy, the patients with high survivin levels exhibited a significantly shorter progression free survival (PFS) than those who had low levels (pellet survivin Hazard Ratio (HR)=2.74, 95% Confidence Interval (CI)=1.31-5.72, p=0.008 and median PFS 5.8 versus 8.6 months, p=0.006, log-rank; cytosolic survivin HR=3.03, 95% CI=1.45-6.35, p=0.003). In contrast, for patients treated with chemotherapy, those with high cytosolic survivin had a significantly longer PFS than those with low levels (median PFS of 6.2 months, versus 4.7 months for patients with low cytosolic concentrations, p=0.024, log-rank). Thus, high levels of survivin are mainly related with a poor response to endocrine therapy, but a good response to chemotherapy. This phenomenon might be related to the different functions of survivin. |
| doi_str_mv | 10.1007/s10549-005-9153-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68637876</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68637876</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-35fbaeff5235e51f924f5351a768c691832e926654ccda4fa40ce6dbf8a1c91f3</originalsourceid><addsrcrecordid>eNpd0V1rFDEUBuAgit1Wf4A3EoR65WhOMvm6lFLbQsEbvQ6ZzEl3yu5kTGYW2l9vlh0oehUOPOclyUvIB2BfgTH9rQCTrW0Yk40FKRr2imxAatFoDvo12TBQulGGqTNyXsojY8xqZt-SM1CyBcH1hjzfDg9bWpZ8GA7DSKeM_RDmQj2dUso0Y5nSWJDOieLYp5CHsQ5bzH56-kK7Za7yIaX-Hxm2uE8rojXV9wc_Buxpl9GXmYbjlN-RN9HvCr5fzwvy-8f1r6vb5v7nzd3V9_smCKnmRsjYeYxRciFRQrS8jVJI8FqZoCwYwdFyVV8UQu_b6FsWUPVdNB6ChSguyOdT7pTTnwXL7PZDCbjb-RHTUpwySmijVYWf_oOPacljvZvjwNtWagMVwQmFnErJGN2Uh73PTw6YO7biTq242oo7tuJY3fm4Bi_dHvuXjbWGCi5X4Evwu5jrBw3lxWlrODNa_AU3PJZM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212445781</pqid></control><display><type>article</type><title>High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>SPAN, Paul N ; TJAN-HEIJNEN, Vivianne C. G ; MANDERS, Peggy ; VAN TIENOVEN, Doorlene ; LEHR, Jeffrey ; SWEEP, Fred C. G. J</creator><creatorcontrib>SPAN, Paul N ; TJAN-HEIJNEN, Vivianne C. G ; MANDERS, Peggy ; VAN TIENOVEN, Doorlene ; LEHR, Jeffrey ; SWEEP, Fred C. G. J</creatorcontrib><description>Variants of survivin with differing subcellular localizations might mediate the different functions of survivin, i.e. cell-cycle regulation and apoptosis inhibition. Highly proliferative tumors are more sensitive to chemotherapy, whereas apoptosis resistant cells would be refractory to endocrine therapy. Possibly, this explains incongruent data on the association of survivin with prognosis in breast cancer. Survivin levels were measured using ELISA in 800 x g pellets and 100,000 x g supernatants of breast cancer tissues from patients that were treated with either chemotherapy or endocrine therapy for advanced disease. These fractions might be enriched with nuclear or cytoplasmatic located survivin variants. Survivin levels were associated with tumors with poor prognostic clinical characteristics. For the patients treated with endocrine therapy, the patients with high survivin levels exhibited a significantly shorter progression free survival (PFS) than those who had low levels (pellet survivin Hazard Ratio (HR)=2.74, 95% Confidence Interval (CI)=1.31-5.72, p=0.008 and median PFS 5.8 versus 8.6 months, p=0.006, log-rank; cytosolic survivin HR=3.03, 95% CI=1.45-6.35, p=0.003). In contrast, for patients treated with chemotherapy, those with high cytosolic survivin had a significantly longer PFS than those with low levels (median PFS of 6.2 months, versus 4.7 months for patients with low cytosolic concentrations, p=0.024, log-rank). Thus, high levels of survivin are mainly related with a poor response to endocrine therapy, but a good response to chemotherapy. This phenomenon might be related to the different functions of survivin.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-005-9153-0</identifier><identifier>PMID: 16541327</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Aromatase Inhibitors - therapeutic use ; Biological and medical sciences ; Breast cancer ; Breast Neoplasms - chemistry ; Breast Neoplasms - drug therapy ; Breast Neoplasms - mortality ; Cancer research ; Cancer therapies ; Chemotherapy ; Endocrine therapy ; Enzyme-Linked Immunosorbent Assay ; Female ; Gynecology. Andrology. Obstetrics ; Hormones ; Humans ; Inhibitor of Apoptosis Proteins ; Mammary gland diseases ; Medical research ; Medical sciences ; Medroxyprogesterone Acetate - therapeutic use ; Microtubule-Associated Proteins - analysis ; Middle Aged ; Neoplasm Proteins - analysis ; Tamoxifen - therapeutic use ; Tumors</subject><ispartof>Breast cancer research and treatment, 2006-07, Vol.98 (2), p.223-230</ispartof><rights>2006 INIST-CNRS</rights><rights>Springer Science+Business Media, Inc. 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-35fbaeff5235e51f924f5351a768c691832e926654ccda4fa40ce6dbf8a1c91f3</citedby><cites>FETCH-LOGICAL-c356t-35fbaeff5235e51f924f5351a768c691832e926654ccda4fa40ce6dbf8a1c91f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17982087$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16541327$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SPAN, Paul N</creatorcontrib><creatorcontrib>TJAN-HEIJNEN, Vivianne C. G</creatorcontrib><creatorcontrib>MANDERS, Peggy</creatorcontrib><creatorcontrib>VAN TIENOVEN, Doorlene</creatorcontrib><creatorcontrib>LEHR, Jeffrey</creatorcontrib><creatorcontrib>SWEEP, Fred C. G. J</creatorcontrib><title>High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><description>Variants of survivin with differing subcellular localizations might mediate the different functions of survivin, i.e. cell-cycle regulation and apoptosis inhibition. Highly proliferative tumors are more sensitive to chemotherapy, whereas apoptosis resistant cells would be refractory to endocrine therapy. Possibly, this explains incongruent data on the association of survivin with prognosis in breast cancer. Survivin levels were measured using ELISA in 800 x g pellets and 100,000 x g supernatants of breast cancer tissues from patients that were treated with either chemotherapy or endocrine therapy for advanced disease. These fractions might be enriched with nuclear or cytoplasmatic located survivin variants. Survivin levels were associated with tumors with poor prognostic clinical characteristics. For the patients treated with endocrine therapy, the patients with high survivin levels exhibited a significantly shorter progression free survival (PFS) than those who had low levels (pellet survivin Hazard Ratio (HR)=2.74, 95% Confidence Interval (CI)=1.31-5.72, p=0.008 and median PFS 5.8 versus 8.6 months, p=0.006, log-rank; cytosolic survivin HR=3.03, 95% CI=1.45-6.35, p=0.003). In contrast, for patients treated with chemotherapy, those with high cytosolic survivin had a significantly longer PFS than those with low levels (median PFS of 6.2 months, versus 4.7 months for patients with low cytosolic concentrations, p=0.024, log-rank). Thus, high levels of survivin are mainly related with a poor response to endocrine therapy, but a good response to chemotherapy. This phenomenon might be related to the different functions of survivin.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Aromatase Inhibitors - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - chemistry</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - mortality</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Endocrine therapy</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Hormones</subject><subject>Humans</subject><subject>Inhibitor of Apoptosis Proteins</subject><subject>Mammary gland diseases</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Medroxyprogesterone Acetate - therapeutic use</subject><subject>Microtubule-Associated Proteins - analysis</subject><subject>Middle Aged</subject><subject>Neoplasm Proteins - analysis</subject><subject>Tamoxifen - therapeutic use</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpd0V1rFDEUBuAgit1Wf4A3EoR65WhOMvm6lFLbQsEbvQ6ZzEl3yu5kTGYW2l9vlh0oehUOPOclyUvIB2BfgTH9rQCTrW0Yk40FKRr2imxAatFoDvo12TBQulGGqTNyXsojY8xqZt-SM1CyBcH1hjzfDg9bWpZ8GA7DSKeM_RDmQj2dUso0Y5nSWJDOieLYp5CHsQ5bzH56-kK7Za7yIaX-Hxm2uE8rojXV9wc_Buxpl9GXmYbjlN-RN9HvCr5fzwvy-8f1r6vb5v7nzd3V9_smCKnmRsjYeYxRciFRQrS8jVJI8FqZoCwYwdFyVV8UQu_b6FsWUPVdNB6ChSguyOdT7pTTnwXL7PZDCbjb-RHTUpwySmijVYWf_oOPacljvZvjwNtWagMVwQmFnErJGN2Uh73PTw6YO7biTq242oo7tuJY3fm4Bi_dHvuXjbWGCi5X4Evwu5jrBw3lxWlrODNa_AU3PJZM</recordid><startdate>20060701</startdate><enddate>20060701</enddate><creator>SPAN, Paul N</creator><creator>TJAN-HEIJNEN, Vivianne C. G</creator><creator>MANDERS, Peggy</creator><creator>VAN TIENOVEN, Doorlene</creator><creator>LEHR, Jeffrey</creator><creator>SWEEP, Fred C. G. J</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20060701</creationdate><title>High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer</title><author>SPAN, Paul N ; TJAN-HEIJNEN, Vivianne C. G ; MANDERS, Peggy ; VAN TIENOVEN, Doorlene ; LEHR, Jeffrey ; SWEEP, Fred C. G. J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-35fbaeff5235e51f924f5351a768c691832e926654ccda4fa40ce6dbf8a1c91f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Aromatase Inhibitors - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - chemistry</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - mortality</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Endocrine therapy</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Hormones</topic><topic>Humans</topic><topic>Inhibitor of Apoptosis Proteins</topic><topic>Mammary gland diseases</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Medroxyprogesterone Acetate - therapeutic use</topic><topic>Microtubule-Associated Proteins - analysis</topic><topic>Middle Aged</topic><topic>Neoplasm Proteins - analysis</topic><topic>Tamoxifen - therapeutic use</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SPAN, Paul N</creatorcontrib><creatorcontrib>TJAN-HEIJNEN, Vivianne C. G</creatorcontrib><creatorcontrib>MANDERS, Peggy</creatorcontrib><creatorcontrib>VAN TIENOVEN, Doorlene</creatorcontrib><creatorcontrib>LEHR, Jeffrey</creatorcontrib><creatorcontrib>SWEEP, Fred C. G. J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SPAN, Paul N</au><au>TJAN-HEIJNEN, Vivianne C. G</au><au>MANDERS, Peggy</au><au>VAN TIENOVEN, Doorlene</au><au>LEHR, Jeffrey</au><au>SWEEP, Fred C. G. J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer</atitle><jtitle>Breast cancer research and treatment</jtitle><addtitle>Breast Cancer Res Treat</addtitle><date>2006-07-01</date><risdate>2006</risdate><volume>98</volume><issue>2</issue><spage>223</spage><epage>230</epage><pages>223-230</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>Variants of survivin with differing subcellular localizations might mediate the different functions of survivin, i.e. cell-cycle regulation and apoptosis inhibition. Highly proliferative tumors are more sensitive to chemotherapy, whereas apoptosis resistant cells would be refractory to endocrine therapy. Possibly, this explains incongruent data on the association of survivin with prognosis in breast cancer. Survivin levels were measured using ELISA in 800 x g pellets and 100,000 x g supernatants of breast cancer tissues from patients that were treated with either chemotherapy or endocrine therapy for advanced disease. These fractions might be enriched with nuclear or cytoplasmatic located survivin variants. Survivin levels were associated with tumors with poor prognostic clinical characteristics. For the patients treated with endocrine therapy, the patients with high survivin levels exhibited a significantly shorter progression free survival (PFS) than those who had low levels (pellet survivin Hazard Ratio (HR)=2.74, 95% Confidence Interval (CI)=1.31-5.72, p=0.008 and median PFS 5.8 versus 8.6 months, p=0.006, log-rank; cytosolic survivin HR=3.03, 95% CI=1.45-6.35, p=0.003). In contrast, for patients treated with chemotherapy, those with high cytosolic survivin had a significantly longer PFS than those with low levels (median PFS of 6.2 months, versus 4.7 months for patients with low cytosolic concentrations, p=0.024, log-rank). Thus, high levels of survivin are mainly related with a poor response to endocrine therapy, but a good response to chemotherapy. This phenomenon might be related to the different functions of survivin.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>16541327</pmid><doi>10.1007/s10549-005-9153-0</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2006-07, Vol.98 (2), p.223-230 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68637876 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Aromatase Inhibitors - therapeutic use Biological and medical sciences Breast cancer Breast Neoplasms - chemistry Breast Neoplasms - drug therapy Breast Neoplasms - mortality Cancer research Cancer therapies Chemotherapy Endocrine therapy Enzyme-Linked Immunosorbent Assay Female Gynecology. Andrology. Obstetrics Hormones Humans Inhibitor of Apoptosis Proteins Mammary gland diseases Medical research Medical sciences Medroxyprogesterone Acetate - therapeutic use Microtubule-Associated Proteins - analysis Middle Aged Neoplasm Proteins - analysis Tamoxifen - therapeutic use Tumors |
| title | High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T10%3A27%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20survivin%20predicts%20a%20poor%20response%20to%20endocrine%20therapy,%20but%20a%20good%20response%20to%20chemotherapy%20in%20advanced%20breast%20cancer&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=SPAN,%20Paul%20N&rft.date=2006-07-01&rft.volume=98&rft.issue=2&rft.spage=223&rft.epage=230&rft.pages=223-230&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-005-9153-0&rft_dat=%3Cproquest_cross%3E68637876%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212445781&rft_id=info:pmid/16541327&rfr_iscdi=true |